Mary Schaheen | President
Prevail Partners Llc

Day 1- World Orphan Drug Congress USA 2025 @ 15:50

Panel: Funding futures: Evaluating investment potential in rare disease and orphan drug markets

In this session, we will evaluate the investment potential within the rare disease and orphan drug markets, exploring the unique opportunities and challenges these sectors present. Attendees will gain insights into the growing demand for innovative treatments for underserved patient populations and the financial implications of developing therapies for rare conditions. We will also discuss the regulatory landscape, funding trends, and key factors influencing investment decisions. By examining the current investment climate and forecasting future trends, this session aims to provide a comprehensive understanding of how to navigate and capitalize on the evolving rare disease and orphan drug landscape.

Moderator: Maha Radhakrishnan, Executive Partner, Sofinnova Investments

×

Maha Radhakrishnan / Panel: Funding futures: Evaluating investment potential in rare disease and orphan drug markets

Maha Radhakrishnan, Executive Partner,
Sofinnova Investments

Maha Radhakrishnan, M.D is currently Executive Partner at Sofinnova Investments and in her most recent role was Consultant to the CEO at Dyne Therapeutics helping with the overarching strategy and direction to the company R&D and Commercialization efforts. Prior to that she was the Chief...

CloseMore

Kevan Oconnor, Venture Investor, Cystic Fibrosis Foundation

×

Kevan Oconnor / Panel: Funding futures: Evaluating investment potential in rare disease and orphan drug markets

Kevan Oconnor, Venture Investor,
Cystic Fibrosis Foundation

Kevan is a life sciences business development and investments professional, and leads infectious disease investments at the CFF. Passionate about partnerships, creativeity, and value creation in the AMR space.  

Close

Christine Brennan, Managing Director, Vertex Ventures HC

Mary Schaheen, President, Prevail Partners Llc

×

Mary Schaheen / Panel: Funding futures: Evaluating investment potential in rare disease and orphan drug markets

Mary Schaheen, President,
Prevail Partners Llc

We are the unique investment partner to life sciences companies providing capital to emerge therapeutics and medical devices developing tomorrow's therapies and treatments.

Close